All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Short hairpin RNA,Gaboxadol
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Connecticut
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 23, 2020
Details:
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Transcend-peptide
Therapeutic Area: Genetic Disease Product Name: xB3
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: CHIESI USA INC
Deal Size: $141.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement June 29, 2020
Details:
The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Personalis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
As part of this research collaboration, Sarepta will be working with the Personalis team to characterize immune response to precision genetic therapeutics, utilizing Personalis’ advanced proprietary analytics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2020
Details:
PPMD and Duchenne UK invite proposals which are investigating ways to mitigate the immune response both in terms of pre-existing immunity and immunity induced by receiving a gene therapy dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stem cell gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rAAVrh8-HexA/HexB
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
Presentations to showcase Axovant's investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-GM2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV capsid-gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2020
Details:
Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Non-viral gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CureDuchenne Ventures
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020
Details:
Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering April 15, 2020
Details:
The Company intends to use the net proceeds for working capital including capital expenditures and research and development expenditures related to the advancement of LUNAR-OTC, LUNAR-COV19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oligonucleotide linked antibody
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: CureDuchenne Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 31, 2020
Details:
The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
